Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms

Kidney International

Volumn 77, Issue 5, 2010, Pages 459-467

  Caplin, Ben ^a,b   Nitsch, Dorothea ^c   Gill, Herpreet ^b   Hoefield, Richard ^d   Blackwell, Scott ^e   MacKenzie, Douglas ^e   Cooper, Jackie A ^f   Middleton, Rachel J ^d   Talmud, Philippa J ^f   Veitch, Peter ^g   Norman, Jill ^a   Wheeler, David C ^a   Leiper, James M ^b,h  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h Genomic Metabolic and Cardiovascular Medicine Section   (United Kingdom)

Author keywords

Nitric oxide; Polymorphisms; Progression of chronic renal failure

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIMETHYLARGININASE; MESSENGER RNA;

ALLELE; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; FEMALE; FUNCTIONAL ASSESSMENT; GENE LOCUS; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; AMIDOHYDROLASES; ARGININE; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENZYME INHIBITORS; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; POLYMORPHISM, GENETIC; RNA, MESSENGER;

EID: 76749111079     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.463     Document Type: Article

References (27)

1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456
2. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. Royal College of Physicians: London, 2008.
3. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
4. Ravani P, Tripepi G, Malberti F et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
5. Fliser D, Kronenberg F, Kielstein JT et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461.
6. Mookerjee RP, Malaki M, Davies NA et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45: 62-71.
7. Boger RH, Bode-Boger SM, Thiele W et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
8. Eid HM, Eritsland J, Larsen J et al. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166: 279-284.
9. Kielstein JT, Bode-Boger SM, Frolich JC et al. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895.
10. Juonala M, Viikari JSA, Alfthan G et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007; 116: 1367-1373. (Pubitemid 47417562)
11. Tran CTL, Fox MF, Vallance P et al. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 2000; 68: 101-105.
12. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-1030.
13. Jacobi J, Maas R, Cordasic N et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 2008; 294: H1058-H1066.
14. Matsumoto Y, Ueda S, Yamagishi S et al. Dimethylarginine dimethyl-aminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18: 1525-1533.
15. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22.
16. Barrett JC, Fry B, Maller J et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
17. Hu T, Chouinard M, Cox AL et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006; 281: 39831-39838.
18. University of Washington Genome Variation Server [Online] 2007 Available from URL: http://gvs.gs.washington.edu/GVS/ accessed 14 February 2008.
19. Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med 2005; 10: S45-S48.
20. Boor P, Sebekova K, Ostendorf T et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22: 3391-3407.
21. Tiret L, Gerdes C, Murphy MJ et al. Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary heart disease-the EARS II study (European Atherosclerosis Research Study). Eur J Clin Invest 2000; 30: 578-585.
22. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006; 1: 1559-1582.
23. Vandesompele J, De PK, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
24. Teerlink T, Nijveldt RJ, de Jong S et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 131-137.
25. Blackwell S, O'Reilly DS, Talwar DK. HPLC analysis of asymmetric dimethylarginine (ADMA) and related arginine metabolites in human plasma using a novel non-endogenous internal standard. Clin Chim Acta 2009; 401: 14-19.
26. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
27. Steele F. Multilevel models for longitudinal data. J R Stat Soc Series B Stat Methodol 2008; 171: 5-19.